Allergy Therapeutics PLC (AGYTF)
OTHER OTC:AGYTF
AGYTF Stock Chart & Stats
$0.11
>-$0.01(-13.33%)
At close: 4:00 PM EST
$0.11
>-$0.01(-13.33%)
Day’s Range― - ―
52-Week Range$0.09 - $0.13
Previous CloseN/A
Volume5.00K
Average Volume (3M)800.00
Market Cap
$625.46M
Enterprise Value$394.82M
Total Cash (Recent Filing)$10.08M
Total Debt (Recent Filing)$26.75M
Price to Earnings (P/E)―
Beta-2.79
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume2,400
30 Day Avg. Volume800
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue6.89
Enterprise Value/Gross Profit16.74
Enterprise Value/Ebitda-12.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$844.77K
Bulls Say, Bears Say
Bulls Say
Focused Allergy Immunotherapy PortfolioAllergy Therapeutics has a clear, focused business model targeting allergen‑specific immunotherapy and next‑generation allergy treatments. This specialization supports deep domain expertise, regulatory know‑how and product lifecycle focus that can sustain competitive positioning over multiple years.
Disease‑modifying Therapeutic ApproachThe company pursues disease‑modifying immunotherapies rather than symptomatic treatments. Such therapies offer durable clinical differentiation, potential for longer treatment value, provider preference and higher barriers to entry — structural advantages for long‑term commercial positioning.
Reported Positive Revenue Growth MetricA reported revenue growth metric (~2.94%) indicates some top‑line resilience versus peers. Modest growth can help sustain R&D and commercialization efforts, supporting product development and incremental scaling without relying solely on one‑off financing events over the coming months.
Bears Say
Stressed Balance Sheet With Negative EquityThe balance sheet shows negative shareholders' equity and a highly adverse debt/equity metric, signaling structural financial weakness. Negative equity constrains financing options, raises creditor risk, and limits strategic flexibility for M&A or large commercial investments over the medium term.
Negative Operating And Free Cash FlowPersistently negative operating and free cash flows and a steep FCF decline imply the company cannot self‑fund operations or R&D. Continued cash burn increases reliance on external capital, heightens dilution or refinancing risk, and undermines sustainable investment in commercialization.
Large Losses And Recent Revenue DeclineSubstantial losses, steep negative margins and a recent material revenue decline indicate weak operating economics. Such structural profitability deficits limit reinvestment capacity, pressure pricing/distribution strategies, and may force cost restructuring or strategic shifts over the coming quarters.
Allergy Therapeutics News
AGYTF FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest stock price was $0.09 and its highest was $0.13 in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is $625.46M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 97 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -$0.005 earnings per share for the quarter, the consensus estimate of -$0.005 by $0.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -$0.005 in its last earnings report, expectations of -$0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in AGYTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.15%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Ownership Overview
Options Prices
Currently, No data available
---